Literature DB >> 2183659

Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects.

M G Kaye1, L J Smith.   

Abstract

Inflammatory mediators such as platelet-activating factor (PAF) and the sulfidopeptide leukotrienes (LT) may contribute to airway hyperreactivity and asthma. PAF has been reported to produce bronchoconstriction and a sustained increase in airway reactivity when inhaled by normal subjects. Leukotrienes produce bronchoconstriction in both normal and asthmatic subjects, but whether they increase airway reactivity is unclear. Before initiating studies to determine how these bioactive mediators influence airway function, we sought to confirm that PAF increases airway reactivity and identify whether one of the sulfidopeptide leukotrienes, LTD4, has a similar effect. Eight normal male subjects inhaled saline and increasing concentrations of either histamine (0.1 to 50 mg/ml), PAF (1 to 1,000 micrograms/ml), or LTD4 (1 to 500 micrograms/ml) on separate days, at least 1 wk apart, until specific airway conductance (SGaw) decreased 50% or the maximal concentration was reached. After inhaling the test substance, methacholine (MCh) challenges were performed at 6 h, at 1, 3, and 7 days, and weekly thereafter until airway reactivity (measured as the MCh concentration that decreased SGaw 35% [PC35SGaw]) normalized. The four postsaline MCh challenges (6 h to 7 days) were used to determine the 95% confidence interval for PC35SGaw (in each subject) and identify significant changes in airway reactivity after inhaling each test substance. Airway reactivity did not change after inhaling histamine. After inhaling PAF, six of eight subjects developed increased airway reactivity, which was maximal at 1 day and persisted for 14 days in three. After inhaling LTD4, six of eight subjects also developed increased airway reactivity, which was maximal at 7 days and persisted for 14 days in two.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183659     DOI: 10.1164/ajrccm/141.4_Pt_1.993

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  13 in total

Review 1.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  The diverse effects of mast cell mediators.

Authors:  Colleen Hines
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

3.  Effect of inhaled prostaglandin D2 in normal and atopic subjects, and of pretreatment with leukotriene D4.

Authors:  S E Sampson; A P Sampson; J F Costello
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

Review 4.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

5.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; C P Page
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

Review 6.  Clinical management of asthma in the 1990s. Current therapy and new directions.

Authors:  P Jain; J A Golish
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 7.  Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.

Authors:  J C Adkins; R N Brogden
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 8.  Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation.

Authors:  I K Taylor
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

9.  Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma.

Authors:  R I Ketchell; M D'Amato; M W Jensen; B J O'Connor
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

10.  Inhaled budesonide fails to inhibit the PAF-induced increase in plasma leukotriene B4 in man.

Authors:  M M Nieminen; E K Moilanen; M O Koskinen; J I Karvonen; L Tuomisto; T J Metsä-Ketelä; H Vapaatalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.